ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Tamoxifen

Criteria

Inclusion Criteria:

• Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy.

• At least 6 lymph nodes examined.

• Good or intermediate tumour differentiation.

• <6 weeks before start of adjuvant therapy.

• Oestrogen or Progesterone positive

Exclusion Criteria:

• Premenopausal.

• Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.

• In-situ/T4 carcinoma.

• Age >80 years.

• World Health Organisation performance index >3.

• Serious accompanying diseases